



## Tessa Therapeutics to Present at the Stifel Healthcare Conference 2022

**SINGAPORE – November 02, 2022 – [Tessa Therapeutics Ltd. \(Tessa\)](#), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, announced that Thomas Willemsen, President and CEO and Dr. Ivan D. Horak, Chief Medical Officer and Chief Scientific Officer, will present at the Stifel Healthcare Conference 2022. The conference is taking place November 15-16, 2022, at Lotte New York Palace Hotel, New York City.**

Details of the presentation are as follows:

<b>Event:</b>	Stifel Healthcare Conference 2022
<b>Date:</b>	Tuesday, November 15, 2022
<b>Time:</b>	8-8:30 a.m. ET
<b>Location:</b>	Lotte New York Palace Hotel, New York, NY

During the conference, Mr. Willemsen, Dr. Horak and Wilson W. Cheung, Chief Financial Officer, will conduct one-on-one meetings with registered investors, showcasing Tessa's business and clinical development strategy, recent corporate achievements, and anticipated milestones.

### About Tessa Therapeutics

Tessa Therapeutics is a clinical-stage biotechnology company developing next-generation cell therapies for the treatment of hematological cancers and solid tumors. Tessa's lead clinical asset, TT11, is an autologous CD30-CAR-T therapy currently being investigated as a potential treatment for relapsed or refractory classical Hodgkin lymphoma as both a monotherapy (Phase 2) and combination therapy (Phase 1b). TT11 has been granted RMAT designation by the FDA and access to the PRIME scheme by European Medicine Agency. Tessa is also advancing an allogeneic "off-the-shelf" cell therapy platform targeting a broad range of cancers in which Epstein Barr Virus Specific T Cells (EBVSTs) are augmented with CD30-CAR. A therapy using this platform is currently the subject of a Phase 1 clinical trial in CD30-positive lymphomas. Tessa has its global headquarters in Singapore, where the company has built a state-of-the-art, commercial cell therapy manufacturing facility. For more information on Tessa, visit [www.tessacell.com](http://www.tessacell.com).

### Cautionary Note on Forward Looking Statements

This press release contains forward-looking statements (within the meaning of the Private Securities Litigation Reform Act of 1995, to the fullest extent applicable) including, without limitation, with respect to various regulatory filings or clinical study developments of the Company. You can identify these statements by the fact that they use words such as "anticipate," "estimate", "expect", "project", "intend", "plan", "believe", "target", "may", "assume" or similar expressions. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties, and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-

looking statements contained in this press release, including, without limitation, those related to the Company's financial results, the ability to raise capital, dependence on strategic partnerships and licensees, the applicability of patents and proprietary technology, the timing for completion of the clinical trials of its product candidates, whether and when, if at all, the Company's product candidates will receive marketing approval, and competition from other biopharmaceutical companies. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made, and disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. The Company's products are expressly for investigational use pursuant to a relevant investigational device exemption granted by the U.S. Food & Drug Administration, or equivalent competent body.

#### **Tessa Therapeutics Investor Contact**

**Wilson W. Cheung**

Chief Financial Officer

[wcheung@tessacell.com](mailto:wcheung@tessacell.com)

#### **Tessa Therapeutics Media Contact**

**[Tiberend Strategic Advisors, Inc.](#)**

**Bill Borden**

+1-732-910-1620

[bborden@tiberend.com](mailto:bborden@tiberend.com)

**Dave Schemelia**

+1-609-468-9325

[dschemelia@tiberend.com](mailto:dschemelia@tiberend.com)